IN8BIO, INC. (INAB) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: July 18, 2025
IN8BIO, INC. (INAB) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
IN8BIO, INC. (Stock Symbol: INAB)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
The organization employs approximately 31 professionals worldwide
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $21 million - Classified as a
small-cap investment offering high growth potential.
Return on Equity (ROE): -248.8% -
Below-average
shareholder return efficiency, indicating areas for operational improvement.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for IN8BIO, INC. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
IN8BIO, INC. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
IN8BIO, INC. Stock Price Chart and Technical Analysis
Loading chart data...
Loading IN8BIO, INC. interactive price chart and technical analysis...
Comprehensive Investment Metrics & Financial Analysis - IN8BIO, INC. (INAB)
Deep dive into IN8BIO, INC.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if IN8BIO, INC. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For IN8BIO, INC.: With a P/E ratio of -0.40, the market sees the stock as potentially undervalued.
P/E Ratio-0.40x
P/B Ratio2.41x
Market Cap$21M
EPS$-0.74
Book Value/Share$0.17
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently IN8BIO, INC. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For IN8BIO, INC.: An ROE of -248.8% indicates room for improvement in shareholder value creation.
ROE-248.8%
ROA-62.3%
ROIC-193.4%
Understanding Financial Health Metrics
What these metrics mean: These ratios assess IN8BIO, INC.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For IN8BIO, INC.: A current ratio of 16.09 indicates strong liquidity.
Current Ratio16.09x
Quick Ratio15.53x
D/E Ratio0.05x
Financial Leverage1.11x
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal IN8BIO, INC.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For IN8BIO, INC.: Free cash flow of $-16M indicates cash challenges that need attention.
Operating Cash Flow$-16M
Free Cash Flow$-16M
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively IN8BIO, INC. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For IN8BIO, INC.:
Understanding Financial Statement Data
What these metrics mean: Key figures from IN8BIO, INC.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For IN8BIO, INC.:
Income Statement ($ Millions)
Operating Income$-32M
Net Income$-31M
R&D Expense$18M
Balance Sheet Highlights ($ Millions)
Total Current Assets$91M
Cash & Short-term Investments$88M
Total Liabilities$10M
Short-term Debt$1M
Dividend & Shareholder Information
Shares Outstanding81M
Growth Metrics (YoY)
EPS Growth-254.3%
IN8BIO, INC. (INAB) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for IN8BIO, INC. stock analysis.
Loading fundamental data...
Loading IN8BIO, INC. comprehensive fundamental analysis and insider trading data...
Latest IN8BIO, INC. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting IN8BIO, INC. (INAB) stock price and investment outlook.
Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient ...
Insiders were net buyers of IN8bio, Inc.'s (NASDAQ:INAB ) stock during the past year. That is, insiders bought more stock than they sold. While insider transactions are not the most important ...
In8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for unmet medical needs, particularly in the field of oncology. The company is actively ...
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial ...
IN8bio, Inc. (NASDAQ:INAB) shareholders (or potential shareholders) will be happy to see that the Independent Director, Emily Fairbairn, recently bought a whopping US$1.5m worth of stock, at a ...
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. ...
IN8bio Inc.INAB is a clinical-stage biotechnology company tackling one of society’s most pressing issues: cancer. Specifically, the company is focused on using the immune system to eliminate ...
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on delivering innovative gamma-delta (γδ) T cell immunotherapies for ...
IN8bio Announces Pricing of $12.4 Million Private Placement Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing expansion cohorts ...
IN8BIO, INC. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of IN8BIO, INC. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - IN8BIO, INC. Stock Forecast
How accurate are IN8BIO, INC. stock predictions?
Our AI model demonstrates 29% historical accuracy for INAB predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence IN8BIO, INC. stock price forecasts?
Based on our AI analysis, IN8BIO, INC. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are IN8BIO, INC. forecasts updated?
IN8BIO, INC. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced IN8BIO, INC. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for IN8BIO, INC. stock.
